| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Medicine, Section of Nephrology, University of Chicago, Chicago, IL 60637;
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205; and
Department of Medicine, Division of Rheumatology, University of Colorado Health Sciences Center, Denver, CO 80262
To investigate the role of complement in lupus nephritis, we used MRL/lpr mice and a transgene overexpressing a soluble complement regulator, soluble CR1-related gene/protein y (sCrry), both systemically and in kidney. Production of sCrry in sera led to significant complement inhibition in Crry-transgenic mice relative to littermate transgene negative controls. This complement inhibition with sCrry conferred a survival advantage to MRL/lpr mice. In a total of 154 animals, 42.5% transgene-negative animals had impaired renal function (blood urea nitrogen > 50 mg/dl) compared with 16.4% mice with the sCrry-producing transgene (p < 0.001). In those animals that died spontaneously, MRL/lpr mice with the sCrry-producing transgene did not die of renal failure, while those without the transgene did (blood urea nitrogen values of 46.6 ± 9 and 122 ± 29 mg/dl in transgene-positive and transgene-negative animals, respectively; p < 0.001). Albuminuria was reduced in those transgenic animals in which sCrry expression was maximally stimulated (urinary albumin/creatinine = 12.4 ± 4.3 and 36.9 ± 7.7 in transgene-positive and transgene-negative animals, respectively; p < 0.001). As expected in the setting of chronic complement inhibition, there was less C3 deposition in glomeruli of sCrry-producing transgenic mice compared with transgene-negative animals. In contrast, there was no effect on glomerular IgG deposition, levels of anti-dsDNA Ab and rheumatoid factor, or spleen weights between the two groups. Thus, long-term complement inhibition reduces renal disease in MRL/lpr mice, which translates into improved survival. MRL/lpr mice in which complement is inhibited still have spontaneous mortality, yet this is not from renal disease.
This article has been cited by other articles:
|
|
 |
|
  M. Sarav, Y. Wang, B. K. Hack, A. Chang, M. Jensen, L. Bao, and R. J. Quigg Renal FcRn Reclaims Albumin but Facilitates Elimination of IgG J. Am. Soc. Nephrol., September 1, 2009; 20(9): 1941 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Abbate, C. Zoja, D. Corna, D. Rottoli, C. Zanchi, N. Azzollini, S. Tomasoni, S. Berlingeri, M. Noris, M. Morigi, et al. Complement-Mediated Dysfunction of Glomerular Filtration Barrier Accelerates Progressive Renal Injury J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1158 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Atkinson, F. Qiao, H. Song, G. S. Gilkeson, and S. Tomlinson Low-Dose Targeted Complement Inhibition Protects against Renal Disease and Other Manifestations of Autoimmune Disease in MRL/lpr Mice J. Immunol., January 15, 2008; 180(2): 1231 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. Le, G. Abbenante, and D. P. Fairlie Profiling the Enzymatic Properties and Inhibition of Human Complement Factor B J. Biol. Chem., November 30, 2007; 282(48): 34809 - 34816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lenderink, K. Liegel, D. Ljubanovic, K. E. Coleman, G. S. Gilkeson, V. M. Holers, and J. M. Thurman The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy Am J Physiol Renal Physiol, August 1, 2007; 293(2): F555 - F564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jiang, J. Foley, N. Clayton, G. Kissling, M. Jokinen, R. Herbert, and M. Diaz Abrogation of Lupus Nephritis in Activation-Induced Deaminase-Deficient MRL/lpr Mice J. Immunol., June 1, 2007; 178(11): 7422 - 7431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miwa, M. A. Maldonado, L. Zhou, K. Yamada, G. S. Gilkeson, R. A. Eisenberg, and W.-C. Song Decay-Accelerating Factor Ameliorates Systemic Autoimmune Disease in MRL/lpr Mice via Both Complement-Dependent and -Independent Mechanisms Am. J. Pathol., April 1, 2007; 170(4): 1258 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, Y. Wang, A. Chang, A. W. Minto, J. Zhou, H. Kang, M. Haas, and R. J. Quigg Unrestricted C3 Activation Occurs in Crry-Deficient Kidneys and Rapidly Leads to Chronic Renal Failure J. Am. Soc. Nephrol., March 1, 2007; 18(3): 811 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Bora, S. Kaliappan, P. Jha, Q. Xu, B. Sivasankar, C. L. Harris, B. P. Morgan, and P. S. Bora CD59, a Complement Regulatory Protein, Controls Choroidal Neovascularization in a Mouse Model of Wet-Type Age-Related Macular Degeneration J. Immunol., February 1, 2007; 178(3): 1783 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bobe, D. Bonardelle, K. Benihoud, P. Opolon, and M. K. Chelbi-Alix Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice Blood, December 15, 2006; 108(13): 3967 - 3975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bagavant, U. S. Deshmukh, H. Wang, T. Ly, and S. M. Fu Role for Nephritogenic T Cells in Lupus Glomerulonephritis: Progression to Renal Failure Is Accompanied by T Cell Activation and Expansion in Regional Lymph Nodes J. Immunol., December 1, 2006; 177(11): 8258 - 8265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Alexander, O.G.B. Aneziokoro, A. Chang, B. K. Hack, A. Markaryan, A. Jacob, R. Luo, M. Thirman, M. Haas, and R. J. Quigg Distinct and Separable Roles of the Complement System in Factor H-Deficient Bone Marrow Chimeric Mice with Immune Complex Disease J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1354 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Sheerin, K. Abe, P. Risley, and S. H. Sacks Accumulation of Immune Complexes in Glomerular Disease Is Independent of Locally Synthesized C3 J. Am. Soc. Nephrol., March 1, 2006; 17(3): 686 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Thurman and V. M. Holers The Central Role of the Alternative Complement Pathway in Human Disease J. Immunol., February 1, 2006; 176(3): 1305 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Alexander, A. Jacob, L. Bao, R. L. Macdonald, and R. J. Quigg Complement-Dependent Apoptosis and Inflammatory Gene Changes in Murine Lupus Cerebritis J. Immunol., December 15, 2005; 175(12): 8312 - 8319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Berger, A. Roos, and M. R. Daha Complement and the kidney: What the nephrologist needs to know in 2006? Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2613 - 2619. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Wenderfer, B. Ke, T. J. Hollmann, R. A. Wetsel, H. Y. Lan, and M. C. Braun C5a Receptor Deficiency Attenuates T Cell Function and Renal Disease in MRLlpr Mice J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3572 - 3582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, I. Osawe, M. Haas, and R. J. Quigg Signaling through Up-Regulated C3a Receptor Is Key to the Development of Experimental Lupus Nephritis J. Immunol., August 1, 2005; 175(3): 1947 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B R Lauwerys and E K Wakeland Genetics of lupus nephritis Lupus, January 1, 2005; 14(1): 2 - 12. [Abstract] [PDF]
|
|
|
|
|
|
M Waldman and M P Madaio Pathogenic autoantibodies in lupus nephritis Lupus, January 1, 2005; 14(1): 19 - 24. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Quigg Complement and the Kidney J. Immunol., October 1, 2003; 171(7): 3319 - 3324. [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, J. Zhou, V. M. Holers, and R. J. Quigg Excessive Matrix Accumulation in the Kidneys of MRL/lpr Lupus Mice Is Dependent on Complement Activation J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2516 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nangaku Complement Regulatory Proteins: Are They Important in Disease? J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2411 - 2413. [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, M. Haas, D. M. Kraus, B. K. Hack, J. K. Rakstang, V. M. Holers, and R. J. Quigg Administration of a Soluble Recombinant Complement C3 Inhibitor Protects Against Renal Disease in MRL/lpr Mice J. Am. Soc. Nephrol., March 1, 2003; 14(3): 670 - 679. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
